R327 shows strong efficacy in lung infection trial Posted on December 3, 2025 by recce_com R327 shows strong efficacy in lung infection trial
WHO 2025 Antibacterial Pipeline Report Posted on October 20, 2025October 20, 2025 by recce_com WHO 2025 Antibacterial Pipeline Report
Recce Pharmaceuticals Targets Diabetic Foot Infections With First-in-Class Synthetic Anti-Infective Posted on October 9, 2025 by recce_com Recce Pharmaceuticals Targets Diabetic Foot Infections With First-in-Class Synthetic Anti-Infective
Recce’s RECCE® 327 Topical Gel targets superbugs, speeds wound healing Posted on August 19, 2025 by recce_com Recce’s RECCE® 327 Topical Gel targets superbugs, speeds wound healing
RECCE® 327 Topical Gel shows strong preclinical results Posted on August 19, 2025August 19, 2025 by recce_com RECCE® 327 Topical Gel shows strong preclinical results
Recce secures $30m debt facility to support Phase III trials Posted on June 18, 2025 by recce_com Recce secures $30m debt facility to support Phase III trials
Break it Down: Recce partners with the US Army Posted on April 28, 2025 by recce_com Break it Down: Recce partners with the US Army
Recce to expand Phase II trial for diabetic foot infections Posted on April 22, 2025 by recce_com Recce to expand Phase II trial for diabetic foot infections
Recce raising up to $15.8m for Phase III trials Posted on April 10, 2025 by recce_com Recce raising up to $15.8m for Phase III trials
Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trial Posted on April 3, 2025 by recce_com Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trial
